MedicareWire

Shop and compare Medicare plans nationwide.

Speak to a Licensed Advisor[1]

1-855-266-4865

Mon-Fri: 8:30 a.m. to 8:00 p.m. ET

  • Medicare Advantage
  • Medicare Part D
  • Medigap
  • Special Needs
  • More➲
    • Senior Dental Insurance
    • Best Medicare Plans
    • MedicareWire Blog
      • Latest Posts
      • Medicare Insurance Plans
      • What Does Medicare Cover?
    • Important Resources
    • Frequently Asked Questions
    • Medicare Glossary
Home › MedicareWire Blog › Trump’s Plan To Reduce Prescription Drug Prices will Help Seniors

Trump’s Plan To Reduce Prescription Drug Prices will Help Seniors

May 15, 2018

On May 11th, President Trump rolled out a comprehensive plan to lower drug prices. The administration’s 44 page executive action on drug pricing, entitled “American Patients First,” is a blueprint that represents the most comprehensive effort by any presidential administration to address the prescription drug price crisis.

The criticism from the mainstream media is that the new effort will accomplish little, because it doesn’t require Medicare to negotiate drug prices. MedicareWire believes the pundits are grossly misinformed. The Trump plan would force a massive change in the pharmaceutical pricing policy that will have a dramatic impact on drug prices, starting with Medicare.

Medicare’s impact on drug prices is largely misunderstood. Many believe the government agency doesn’t negotiate drug prices, but it does and has done so since the Medicare Part D program was enacted in 2003. Medicare’s negotiating process has resulted in Part D spending coming in significantly under budget, representing the most successful cost-control effort in the history of the Medicare program.

In a 2014 report the Congressional Budget Office reported, “The competitive structure of Part D gives plan sponsors significant incentive to hold down spending… sponsors use three main approaches: They encourage the use of less-expensive brand-name drugs, they negotiate lower prices for brand-name drugs, and they encourage the use of generic drugs.”

If the Trump administration’s plan is enacted, it would significantly change how drugs are purchased and sold among drug companies, insurers, and industry middlemen. Some of the changes would lower the out-of-pocket costs Americans pay at the pharmacy, especially for Medicare beneficiaries. One suggestion would end the gag clauses that prevent pharmacists from discussing lower-cost alternatives with consumers.

The Trump plan outlines two types of reform: (1) things the administration can do on its own, and (2) things Congress must enact. While the announcement highlighted the administration’s unilateral actions, the Congressional role is critical to future success. As the President commented, “These reforms are just the beginning. In the coming weeks, we will work with Congress to pass legislation that will save Americans even more money at the pharmacy. For that, we need the help of Congress, and we think it will be forthcoming.”

The Trump administration proposes limiting the growth of Medicare payments for drugs administered by doctors under Medicare Part B coverage to consumer inflation. This change is estimated to save tens of billions of dollars over time. It also clamps down on the ability of drug companies to exploit the system with massive price hikes on old drugs.

In addition to the Part B controls, the administration proposes moving drugs out of Part B into Part D, thus increase the number of drugs that fall under Part D’s negotiating capability. At the same time, the administration is evaluating a rollback on previous mandates that require Medicare to keep prohibitively expensive drugs on its formularies.

The Trump administration plan considers numerous ideas for addressing the issue of high drug prices, including:

  • Reforming the FDA’s internal procedures in order to reduce artificial barriers to generic competition.
  • Promoting the use of biosimilars (i.e., generic biotechnology drugs) and reducing barriers to their take-up.
  • Preventing branded drug manufacturers from gaming FDA risk management strategies and 180-day generic launch rules to forestall generic competition.
  • Providing avenues for Medicare to bulk-purchase costly drugs so as to limit the pricing power of monopolies.
  • Requiring drug rebates negotiated by PBMs to be passed directly on to the patients using those drugs, instead of being used to reduce premiums for all policyholders. This should incentivize more and wider use of rebates, because price-sensitive consumers will benefit from lower prices on the drugs they themselves use.
  • Requiring drug companies to disclose list prices for their drugs in television ads, just as they do for side effects and other drug risks. This should make companies think twice about charging egregious prices, knowing that there will be a PR blowback.

President Trump and HHS Secretary Alex Azar say this is just the start. Meanwhile, it’s time for Congress to do its part. Specifically, Congress should address two laws that have worked behind the scene to drive up the cost of prescription drugs: the Orphan Drug Act of 1983, which allows drug companies to charge outrageous prices for drugs meant to treat rare diseases; and the Biologics Price, Competition, and Innovation Act of 2009, which has done little to promote competition for off-patent biotech drugs. Congress should also pass legislation that helps the Federal Trade Commission to unravel the U.S. drug rebate system. Rebates to pharmacy benefits managers, or PBMs, totaled $129 billion in 2017, according IQVIA, a firm that tracks the drug industry. PBMs are companies, including CVS/Caremark and Express Scripts, that act as middlemen between drug and insurance companies. They’re getting rich at the public’s expense.

 

Article by David Bynon / MedicareWire Blog

Do Low-Cost Medicare Supplement Plans Save Money?

Medicare supplement insurance premiums continue to increase. The increases have a lot to do with changes brought about by the Affordable Care Act (aka, Obama) and how these changes affect reimbursements to health care providers. As a result, a lot of seniors are asking about low-cost Medicare … [Read More...]

Is CMS Biased in Favor of Medicare Advantage?

While studying Medicare & You 2021: The official U.S. government Medicare handbook to look for changes coming in the new year (which you can download here), the MedicareWire staff began noticing language and diagrams that it felt would bias readers. In fact, once you start looking for it, you … [Read More...]

2021 Medicare Open Enrollment: A Guide to Dates, Costs and Eligibility

Everything you need to know about Medicare's Annual Election Period (AEP) dates, costs, eligibility, and opportunities to change your Medicare insurance coverage this Fall. What’s in this 2021 Medicare AEP guide? When is Medicare Open Enrollment for 2021 Coverage? How to Enroll in … [Read More...]

Does Medicare Cover Physical Therapy After An Accident or Surgery?

Does Medicare Cover Physical Therapy? If you’re covered by Medicare and have an illness or injury that requires physical therapy, you may wonder, “what does Medicare cover?” More specifically, you’ll likely want to know does Medicare cover physical therapy? In this article, we will look at … [Read More...]

Does Medicare Cover Eye Exams for Seniors?

Does Medicare Cover Eye Exams? With Original Medicare, you have coverage for all of the routine checkups and preventative care you need. But what about your eyes? If you are wondering if your medicare benefits cover visits to the eye doctor, you might be surprised by the answer: Original … [Read More...]

More Posts from this Category

Related Topics

[1] Licensed Sales Agent

Licensed sales agent (“advisor”) services are provided by HealthPlanOne, LLC, MedicareWire’s trusted partner. Read our full sales agent disclosure.

[2] Trademark Notice

MedicareWire uses legal U.S. trademarks to identify and describe Medicare and other insurance products for shoppers. See our full trademark use disclosure.

About MedicareWire

  • About
  • Contact
  • Connect with Us!
  • Privacy
  • Disclosure
  • Medicare Supplement Reviews

Copyright © 2021 MedicareWire.com - All Rights Reserved

Who is MedicareWire?
David Bynon
Chief Petty Officer David Bynon re-enlisting 15 September 2001.

Hello, my name is David Bynon.

I founded MedicareWire in 2011 after retiring from the Navy. I’ve made helping people like you my full-time retirement profession.

My goal is to help you see all the rates offered by insurance companies that sell Medigap policies in your area.

I am not an insurance agent.

My job is to make sure that you have the information you need to be comfortable with your plan decision. When it comes to choosing a Medigap plan, I want you to be able to see all rates and carriers before speaking with an agent.

To provide you with this free service, I need to ask you to provide your age, gender, zip code, and email address. I promise to keep your information secure. You can count on me not to share, sell, or otherwise divulge your information to anyone.

Yours in Better Medicare.

David Bynon

Medigap Quotes by Email: Compare and Save!


Complete this form and MedicareWire will send you a complete rate analysis on Medigap plans in your area. This is a free service with no obligations.

Answers to the following questions will allow us to get accurate information for you. These are some of the same questions you will be asked when you apply for insurance. We will not sell, provide, or otherwise disclose the information you provide to anyone.

  • This field is for validation purposes and should be left unchanged.